ANDA 78179, held by Actavis Elizabeth. Zolpidem Tartrate.
As of Nov 16, 2026, ANDA 78179 (Zolpidem Tartrate), held by Actavis Elizabeth, was first approved by FDA on Jun 6, 2011, with 5 approved supplements and 0 published complete response letters.
| Jun 6, 2011 | Original application | Approved | None posted |
| Oct 13, 2010 | Original application | Approved |
| Zolpidem Tartrate12.5MG · tablet, extended release;oral | Zolpidem Tartrate | Discontinued |
| Zolpidem Tartrate6.25MG · tablet, extended release;oral | Zolpidem Tartrate | Discontinued |
| Nov 19, 2019 | Supplement 14Labeling · Standard review | Approved | None posted |
| Nov 19, 2019 | Supplement 15Labeling · Standard review | Approved | None posted |
| Nov 19, 2019 | Supplement 16Labeling · Standard review | Approved | None posted |
| Mar 28, 2016 | Supplement 12Labeling · Standard review | Approved | None posted |
| Dec 21, 2014 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jun 6, 2011 | Original application | Approved | None posted |
| Oct 13, 2010 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters